Although cancer immunotherapy has transformed treatment by harnessing the immune system to eliminate tumors, only a small ...

GeoVax believes Gedeptin’s unique mechanism of localized tumor destruction combined with immune activation positions the program within a growing area of oncology focus: therapies designed to overcome ...

Researchers at Moffitt Cancer Center report encouraging early results from a phase 2 study examining whether immunotherapy ...

New research reveals PD-1 inhibitors may compromise the blood-brain barrier, influencing cancer treatment outcomes and brain ...

A USC study finds immunotherapy increases PAD risk by 60%. Experts advise vascular monitoring to help prevent limb loss in ...

Immune checkpoint inhibition disrupts receptor–ligand checkpoint signaling that restrains immunity, thereby enabling T-cell–mediated cancer-cell killing while increasing risk of autoimmune-like ...

Ultimately, Dr. Minn notes, success in immuno-oncology will be measured in multiple ways: Scientifically, by the depth of ...

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies. However, nearly half of patients show limited ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering ...

Baseline stool metagenomic profiling in CheckMate 915 linked specific bacterial taxa with recurrence-free survival after ...

Immune system activation and activity is regulated through stimulatory or inhibitory ligand-receptor interactions collectively termed immune checkpoints. 1 Stimulatory interactions give the immune ...